Russia Attracts More Multinational Pharmas As Emerging Markets Continue To Bloom
• By PharmAsia News
Indian drug maker Ranbaxy is moving swiftly to capitalize on Russian policies to encourage establishing a local production presence, signing a memorandum of understanding with Russia's Yaroslavl regional authority to help the province build a medical and pharmaceutical center. The "going local, going to regions" move could set a model for international pharma companies eying the Russian market, says a Russia biologics expert
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.